In a study with guinea pigs, plant cannabinoids such as THC, CBD, CBC, CBG, CBDA, and THCV were used to assess whether they have any effect on bronchoconstriction, inflammation, and coughing. It was found that all three parameters were reduced by THC via activation of CB1 and CB2 (Makwana et al., 2015). CBD inhibited coughing and THCV decreased inflammatory leucocyte recruitment, whereas other cannabinoids did not produce any effect.
In the ovalbumin rat model of asthma, serum levels of all analyzed cytokines such as IL-4, IL-5, IL-13, IL-6, and TNF-α but not IL-10 were decreased upon treatment with CBD (5 mg/kg, i.p.). This suggests that CBD may have a therapeutic potential in inhibiting lung inflammation (Vuolo et al., 2015).
In the LPS mouse model of lung inflammation, pparγ-dependent G-CSF secretion by mast cells and subsequent myeloid-derived suppressor cell mobilization were induced by CBD (20 mg/kg i.p.) (Hegde et al., 2015).
In human patients, anandamide was observed to be involved in suppressing bronchospasms and coughing via activation of CB1 receptors (Calignano et al., 2000).